Plasma levels of HBV pregenomic RNA before and after nucleos(t)ide analogue treatment

被引：0
|
作者：
Jansen, Louis [1 ,2 ]
van Dort, Karel A. [1 ]
Zaaijer, Hans L. [3 ]
Kootstra, Neeltje A. [1 ]
Reesink, Hendrik W. [2 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Virol, NL-1105 AZ Amsterdam, Netherlands
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1079
引用
收藏
页码：729A / 730A
页数：2
相关论文
共 50 条
  • [21] Limited Value of HBV-RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative Hepatitis B Patients
    Ohlendorf, Valerie
    Wuebbolding, Maximilian
    zu Siederdissen, Christoph Hoener
    Bremer, Birgit
    Deterding, Katja
    Wedemeyer, Heiner
    Cornberg, Markus
    Maasoumy, Benjamin
    JOURNAL OF VIRAL HEPATITIS, 2025, 32 (04)
  • [22] Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy
    Anderson, Mark
    Gersch, Jeffery
    Luk, Ka-Cheung
    Dawson, George
    Carey, Ivana
    Agarwal, Kosh
    Shah, Pir
    Dusheiko, Geoffrey
    Lau, Daryl
    Cloherty, Gavin
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (11) : 2029 - 2031
  • [23] Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B
    Chotiyaputta, Watcharasak
    Peterson, Carolyn
    Ditah, Fausta A.
    Goodwin, Diane
    Lok, Anna S. F.
    JOURNAL OF HEPATOLOGY, 2011, 54 (01) : 12 - 18
  • [24] Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions
    Zhong, Jian-Hong
    TUMOR BIOLOGY, 2014, 35 (12) : 12779 - 12784
  • [25] CHANGES OF HBSAG LEVELS IN PATIENTS WITH EFFECTIVE NUCLEOS(T)IDE ANALOGUE THERAPY - COMPARISON OF DIFFERENT TREATMENT REGIMENS
    Jochum, Christoph
    Thon, Sebastian
    Timm, Joerg
    Roggendorf, Michael
    Canbay, Ali
    Gerken, Guido
    Schlaakl, Joerg F.
    HEPATOLOGY, 2010, 52 (04) : 531A - 531A
  • [26] Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t) ide Analogue Treatment?
    Gao, Yuhua
    Li, Yutang
    Meng, Qinghua
    Zhang, Zhanqing
    Zhao, Ping
    Shang, Qinghua
    Li, Yue
    Su, Mingze
    Li, Tong
    Liu, Xueen
    Zhuang, Hui
    JOURNAL OF CLINICAL MICROBIOLOGY, 2017, 55 (10) : 2972 - 2982
  • [27] Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment
    Xia, Muye
    Liao, Guichan
    Chen, Hongjie
    Wu, Yin
    Fan, Rong
    Zhang, Xiaoyong
    Peng, Jie
    CLINICAL IMMUNOLOGY, 2019, 198 : 31 - 38
  • [28] HBV PGRNA DYNAMICS CHARACTERISTICS AMONG CHRONIC HEPATITIS B PATIENTS RECEIVING NUCLEOS(T)IDE ANALOGUE TREATMENT.
    Luo, Hao
    Xu, Jinghang
    Cheng, Ran
    Han, Yifan
    Kang, Qian
    Tan, Ning
    Pan, Jiali
    Chen, Hongyu
    Yang, Yuqing
    Xu, Xiaoyuan
    HEPATOLOGY, 2020, 72 : 442A - 443A
  • [29] Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues
    Jansen, L.
    Kootstra, Neeltje A.
    van Dort, Karel A.
    Takkenberg, R. Bart
    Reesink, Hendrik W.
    Zaaijer, Hans L.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (02): : 224 - 232
  • [30] Should Level of HBV RNA be Used to Determine When Patients Should Stop Treatment With Nucleos(t)ide Analogues
    Otsuka, Motoyuki
    Koike, Kazuhiko
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (03) : 551 - 552
12345